Pharmacokinetics of fingolimod (FTY720) and a combined oral contraceptive coadministered in healthy women: Drug-drug interaction study results

International Journal of Clinical Pharmacology and Therapeutics

Volumn 50, Issue 8, 2012, Pages 540-544

  David, Olivier J ^a   Ocwieja, Magdalena ^a   Meiser, Karin ^a   Emotte, Corinne ^a   Jakab, Annamaria ^a   Wemer, Johan ^b   Den Daas, Izaak ^b   Schmouder, Robert ^c  

^a NOVARTIS PHARMA AG   (Switzerland)

^b QPS Netherlands BV   (Netherlands)

^c NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Combined oral contraceptive; Drug drug interaction; Ethinylestradiol; Fingolimod; Levonorgestrel; Pharmacokinetics

Indexed keywords

ETHINYLESTRADIOL PLUS LEVONORGESTREL; FINGOLIMOD;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; BIRTH CONTROL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG EFFICACY; FATIGUE; FEMALE; HEADACHE; HEART RATE; HUMAN; LOADING DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; OROPHARYNX PAIN; PLASMA CONCENTRATION-TIME CURVE; PRESYNCOPE; RHINOPHARYNGITIS; SIDE EFFECT; STEADY STATE; VAGINA BLEEDING; VAGINA DISCHARGE;

ADOLESCENT; ADULT; AREA UNDER CURVE; CONTRACEPTIVES, ORAL, COMBINED; DRUG INTERACTIONS; ETHINYL ESTRADIOL; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEVONORGESTREL; PROPYLENE GLYCOLS; SPHINGOSINE;

EID: 84864630365     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP201675     Document Type: Article

References (8)

1. Brinkmann V, Billich A, Baumruker T, Heining P, Schmouder R, Francis G, Aradhye S, Burtin P. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov. 2010; 9: 883-897. doi:10.1038/nrd3248 PubMed
2. Novartis (2011) Full prescribing information Gilenya (fingolimod). Available at: http://www.pharma.us.novartis.com/product/pi/pdf/gilenya.pdf (accessed 3 February 2011).
3. David OJ, Kovarik JM, Schmouder RL. Clinical pharmacokinetics of fingolimod. Clin Pharmacokinet. 2012; 51: 15-28. doi:10.2165/11596550-000000000- 00000 PubMed
4. Kovarik JM, Schmouder RL, Barilla D, Büche M, Rouilly M, Berthier S, Wang Y, Van Saders C, Mayer T, Gottlieb AB. FTY720 and cyclosporine: evaluation for a pharmacokinetic interaction. Ann Pharmacother. 2004; 38: 1153-1158. doi:10.1345/aph.1E035 PubMed (Pubitemid 38802151)
5. Center for Drug Evaluation and Research [CDER]. Application number: 22-527. Clinical pharmacology and biopharmaceutics review(s) [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2010/ 022527Orig1s000clinpharmr.pdf [Accessed 2012 Feb 8].
6. Guengerich FP. Oxidation of 17 alpha-ethynylestradiol by human liver cytochrome P-450. Mol Pharmacol. 1988; 33: 500-508. PubMed
7. Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L; TRANSFORMS Study Group. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010; 362: 402-415. doi:10.1056/NEJMoa0907839 PubMed
8. Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P; FREEDOMS Study Group. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010; 362: 387-401. doi:10.1056/NEJMoa0909494 PubMed